SCHEMBL4175236

SCHEMBL4175236

CON(C)C(=O)CCCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.52
GPR119 Q8TDV5 13/20 0.50
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2547405 0.92 GPR119 (0.47) FAAHGPR119KDM4EPKMHPGD
SCHEMBL1329227 0.85 GPR119 (0.48) FAAHGPR119KDM4EPKMHPGD
SCHEMBL15085741 0.82 GPR119 (0.59) FAAHGPR119KDM4EPKMHPGD
SCHEMBL6794692 0.81 FAAH (0.56) FAAHGPR119KDM4EPKMHPGD
SCHEMBL20077080 0.81 FAAH (0.58) FAAHGPR119KDM4EPKMHPGD
SCHEMBL544238 0.81 FAAH (0.58) FAAHGPR119KDM4EPKMHPGD
SCHEMBL13999420 0.81 FAAH (0.58) FAAHGPR119KDM4EPKMHPGD
SCHEMBL29365972 0.81 GPR119 (0.44) GPR119KDM4EPKMHPGD
SCHEMBL21783763 0.81 GPR119 (0.44) GPR119KDM4EPKMHPGD
SCHEMBL21783667 0.81 GPR119 (0.44) GPR119KDM4EPKMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090111778-A1 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US claimed
EP-1954137-A4 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2008-12-17 EP claimed
EP-1954137-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-13 EP claimed
WO-2007061862-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 WO claimed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed
US-20090111778-A1 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
EP-1954137-A4 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2008-12-17 EP disclosed
EP-1954137-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-13 EP disclosed
WO-2007061862-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 WO disclosed
US-6399619-B1 PREVENTION AND TREATMENT OF AIDS AND VIRAL INFECTION BY HIV MERCK & CO., INC. 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 FAAH 1/4885GPR119 213/4885KDM4E 1442/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 FAAH 1/4885GPR119 213/4885KDM4E 1442/4885
US-20090111778-A1 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase FAAH, FAAH2, HCRTR2 FAAH 1/4885GPR119 159/4885KDM4E 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.